Guadecitabine

Summary

Guadecitabine (CHEMBL3544916) is a phase-3 clinical-stage small molecule; indicated across 12 conditions including acute myeloid leukemia and hepatocellular carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 12 conditions
• Clinical trials: 32
• Chemistry: 557.4 Da · C18H24N9O10P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3544916
Name	Guadecitabine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	135564655
Molecular formula	C18H24N9O10P
Molecular weight	557.4
InChIKey	GUWXKKAWLCENJA-WGWHJZDNSA-N

SMILES: C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2N=C(NC3=O)N)COP(=O)(O)O[C@H]4C[C@@H](O[C@@H]4CO)N5C=NC(=NC5=O)N)O

IUPAC name: [(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl [(2R,3S,5R)-5-(4-amino-2-oxo-1,3,5-triazin-1-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate

Also known as: Guadecitabina, Guadecitabine, SGI-110, Sgi-110 free acid, GUADECITABINE

Parent form; salt/anhydrous children: CHEMBL3544980

Patent coverage: 355 distinct patent families (937 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 935 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

12 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
acute myeloid leukemia	3	MONDO:0018874	EFO:0000222
hepatocellular carcinoma	2	MONDO:0007256	EFO:0000182
myelodysplastic syndrome	2	MONDO:0018881	EFO:0000198
small cell lung carcinoma	2	MONDO:0008433	EFO:0000702
urothelial carcinoma	2	MONDO:0040679	EFO:0008528
ovarian cancer	2	MONDO:0008170	MONDO:0008170
clear cell renal carcinoma	1	MONDO:0005005	EFO:0000349
germ cell tumor	1	MONDO:0005040	EFO:0000514
metastatic melanoma	1	MONDO:0005191	EFO:0002617
colorectal adenocarcinoma	1	MONDO:0005008	EFO:0000365
lung neoplasm	1	MONDO:0021117	MONDO:0008903

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 32.

Phase distribution

Phase	Trials
PHASE2	14
PHASE1	9
PHASE1/PHASE2	6
PHASE3	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02348489	PHASE3	COMPLETED	SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction
NCT02907359	PHASE3	COMPLETED	Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs
NCT02920008	PHASE3	COMPLETED	Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
NCT02935361	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
NCT03179943	PHASE2	ACTIVE_NOT_RECRUITING	Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma
NCT03308396	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer
NCT04340843	PHASE2	ACTIVE_NOT_RECRUITING	Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
NCT01261312	PHASE1/PHASE2	COMPLETED	SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
NCT01696032	PHASE2	COMPLETED	SGI-110 in Combination With Carboplatin in Ovarian Cancer
NCT01752933	PHASE2	COMPLETED	SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
NCT01896856	PHASE1/PHASE2	COMPLETED	Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
NCT02096055	PHASE2	COMPLETED	Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
NCT02131597	PHASE2	COMPLETED	Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes
NCT02197676	PHASE2	COMPLETED	A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response
NCT02684162	PHASE2	COMPLETED	Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant
NCT02901899	PHASE2	COMPLETED	Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT03075826	PHASE2	COMPLETED	A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms
NCT03165721	PHASE2	TERMINATED	A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
NCT03206047	PHASE1/PHASE2	COMPLETED	Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT03454984	PHASE2	UNKNOWN	SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation
NCT03576963	PHASE1/PHASE2	WITHDRAWN	Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer
NCT03603964	PHASE2	TERMINATED	Guadecitabine Extension Study
NCT03913455	PHASE2	COMPLETED	Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer
NCT02998567	PHASE1	ACTIVE_NOT_RECRUITING	Combination Study of Guadecitabine/ASTX727 and Pembrolizumab
NCT03220477	PHASE1	ACTIVE_NOT_RECRUITING	Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.
NCT03257761	PHASE1	ACTIVE_NOT_RECRUITING	Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
NCT01966289	PHASE1	COMPLETED	SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)
NCT02293993	PHASE1	COMPLETED	Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia
NCT02429466	PHASE1	COMPLETED	Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors
NCT02608437	PHASE1	UNKNOWN	A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients
NCT02892318	PHASE1	COMPLETED	A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)
NCT03085849	PHASE1	COMPLETED	SGI-110 Plus Durvalumab/Tremelimumab in SCLC

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).